Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Does alcohol kill brain cells?

Several origins have been suggested for the idea that alcohol kills brain cells. Some link it to the temperance movement, which called for prohibition of alcohol.

9 Jul 2012

Review confirms impaired cognition in prodromal psychosis

Patients at high risk for psychosis show significant and widespread impairments in neurocognitive functioning and social cognition, results from a systematic review and meta-analysis of published studies show.

28 Jun 2012

Family history influences age at prodrome and psychosis onset

A family history of psychosis is associated with an earlier age at onset of both prodromal symptoms and full-blown psychosis, US research shows.

28 Jun 2012

Review confirms impaired cognition in prodromal psychosis

27 Jun 2012

Amygdala volume reduced in schizophrenia, not psychotic BD

Amygdala volume is reduced in patients with schizophrenia compared with those who have psychotic bipolar disorder, researchers report.

22 Jun 2012

Childhood viral CNS infections increase psychosis risk

Viral infections of the central nervous system in childhood are associated with nearly a two-fold increased risk for non-affective psychosis and schizophrenia in adulthood, a review and meta-analysis of published studies shows.

20 Jun 2012

Insight linked to gray matter volume in FEP patients

Results from an Irish study show that poor insight is associated with increased gray matter volume in subcortical and frontotemporal brain regions among patients with first-episode psychosis, but not in those with chronic schizophrenia.

20 Jun 2012

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Sunovion Pharmaceuticals Canada Inc. today announced that the New Drug Submission (NDS) for LATUDA (lurasidone HCl), for the treatment of adult patients with acute schizophrenia has been approved by Health Canada.

16 Jun 2012

Emotion perception impaired in patients at risk for psychosis

Patients at ultra-high risk for psychosis, as well as those with first-episode schizophrenia, show significant impairments in facial and vocal emotion recognition, researchers report.

15 Jun 2012

Preterm birth increases psychiatric disorder risk

Individuals born preterm are at increased risk for a range of psychiatric disorders in young adulthood, researchers report.

14 Jun 2012

Hot weather increases death risk in psychosis patients

Hot weather is associated with increased mortality rates among patients with psychosis, dementia, or substance use disorder, UK research shows.

13 Jun 2012

Low pre-morbid IQ not associated with psychosis risk

The strong correlations currently observed between low IQ and risk for psychosis are most likely linked to the influence that psychosis onset has on cognitive functioning rather than a shared genetic background, suggest study findings.

7 Jun 2012

Over half of FEP patients achieve symptomatic remission

More than half of patients with a first episode of psychosis achieve symptomatic remission after 2 years of treatment, but recovery rates are lower, results from a Singaporean study show.

31 May 2012

Delirium has protracted course in elderly care home residents

Episodes of delirium in elderly care home residents tend to be protracted, typically being preceded and/or followed by subacute symptomatology, a prospective cohort study indicates.

30 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Scientists, students share latest innovations in mental health at 13th Annual Research Half Day

Today, local scientists and students are sharing leading research in mental health. The 13th Annual Research Half Day, hosted by Lawson Health Research Institute and St. Joseph's Health Care London's Regional Mental Health Care (RMHC) London and St. Thomas, will present science that could change the course of patient care.

17 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012